Paper Review Records
全部论文审稿周期
19 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
64
天
121
天
Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy
作者
Takeshi Sasaki; Shinichiro Higashi; Kouhei Nishikawa; Koji Iinuma; Keita Nakane; Tomoki Taniguchi; Yuta Sano; Aika Matsuyama; Kaori Ozawa; Kosuke Tochigi; Masataka Tamura; Yasuaki Kubota; Shusuke Akamatsu; Takuya Koie; Takahiro Inoue展开收起
作者单位
1. Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan; 2. Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan; 3. Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan; 4. Department of Urology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan; 5. Department of Urology, Gifu Prefectural General Medical Center, Gifu, Japan; 6. Department of Urology, Yokkaichi Municipal Hospital, Yokkaichi, Japan; 7. Department of Urology, Okazaki City Hospital, Okazaki, Japan; 8. Department of Urology, Toyota Memorial Hospital, Toyota, Japan; 9. Tsu, Japan展开收起
102
天
Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer
作者
Yusuke Kawanaka; Chiaki Inagaki; Masaki Okura; Seiichiro Mitani; Naoki Shiraishi; Kazuko Sakai; Kazuto Nishio; Yutaka Kimura; Yasutaka Chiba; Tomoko Wakasa; Hisato Kawakami; Hidetoshi Hayashi展开收起
作者单位
1. Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Japan; 2. Genome Medical Center, Kindai University Hospital, Sakai, Japan; 3. Department of Genome Biology, Kindai University Faculty of Medicine, Sakai, Japan; 4. Department of Surgery, Kindai University Nara Hospital, Ikoma, Japan; 5. Clinical Research Center, Kindai University Hospital, Sakai, Japan; 6. Department of Diagnostic Pathology, Kindai University Nara Hospital, Ikoma, Japan; 7. Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan展开收起
136
天
Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma
作者
Takumi Kinomoto; Kenji Ikezawa; Kunihito Gotoh; Yugo Kai; Ryoji Takada; Takanori Masumoto; Masaki Kawabata; Hiroki Kishimoto; Kana Ito; Makiko Urabe; Kaori Mukai; Tasuku Nakabori; Minoru Shigekawa; Hirofumi Akita; Hidenori Takahashi; Shogo Kobayashi; Kazuyoshi Ohkawa展开收起
作者单位
1. Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan; 2. Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan; 3. Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan; 4. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan; 5. Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan展开收起
53
天
High therapeutic efficacy of triplet therapy in unresectable or metastatic colorectal cancer and its optimal application strategies
作者
Hiroki Sakuyama; Hiroyuki Okuyama; Yoriyuki Tahara; Sena Tsukamoto; Ikuhiro Kita; Kotone Nomura; Akitsu Murakami; Yoshihiro Okita; Hironaga Satake; Takeshi Kato; Akihito Tsuji展开收起
作者单位
1. Department of Medical Oncology, Kagawa University Hospital, Miki, Japan; 2. Department of Medical Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan; 3. Department of Medical Oncology, Kochi Medical School, Nankoku, Japan; 4. Department of Surgery, NHO Osaka National Hospital, Osaka, Japan展开收起
110
天
Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer
作者
Neal Shore; Nguyen; Barinder Kang; Amrita Sawhney; Clare Byrne; Jackson Tang; Magdaliz Gorritz; Chi-Chang Chen; Jeetvan Patel展开收起
作者单位
1. START Carolinas/Carolina Urologic Research Center, Myrtle Beach, USA; 2. Novartis Pharmaceuticals Corporation, East Hanover, USA; 3. Asclepius Analytics, New York, USA; 4. IQVIA, Wayne, USA展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天